1
Blennow, K, de Leon, MJ & Zetterberg, H (2006) Alzheimer's disease. Lancet
368, 387–403.
2
Roses, A, Alberts, M & Strittmatter, W (1992) Alzheimer's disease – reassessing the data. Curr Biol
2, 7–9.
3
Brookmeyer, R, Johnson, E, Ziegler-Graham, K, et al. (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement
3, 186–191.
4
Ferri, CP, Prince, M, Brayne, C, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet
366, 2112–2117.
5
Dementia across Australia 2011–2050 (2011) .
6
.
7
Kidd, PM (2008) Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev
13, 85–115.
8
Verdile, G, Fuller, S, Atwood, CS, et al. (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?
Pharmacol Res
50, 397–409.
9
Borroni, B, Akkawi, N, Martini, G, et al. (2002) Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci
203–204, 189–193.
10
Krishnaswamy, S, Verdile, G, Groth, D, et al. (2009) The structure and function of Alzheimer's gamma secretase enzyme complex. Crit Rev Clin Lab Sci
46, 282–301.
11
De Strooper, B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev
90, 465–494.
12
Castellani, RJ, Lee, HG, Siedlak, SL, et al. (2009) Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis
18, 447–452.
13
Ballatore, C, Lee, VM & Trojanowski, JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci
8, 663–672.
14
Small, SA & Duff, K (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron
60, 534–542.
15
Liang, Z, Liu, F, Iqbal, K, et al. (2009) Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis
17, 531–539.
16
Iqbal, K, Liu, F, Gong, CX, et al. (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol
118, 53–69.
17
Corder, EH, Saunders, AM, Strittmatter, WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science
261, 921–923.
18
Di Paolo, G & Kim, TW (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci
12, 284–296.
19
Han, X (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta
1801, 774–783.
20
Han, X & Gross, RW (2005) Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev
24, 367–412.
21
Frisardi, V, Panza, F, Seripa, D, et al. (2011) Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog Lipid Res
50, 313–330.
22
Farooqui, AA, Farooqui, T, Panza, F, et al. (2012) Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci
69, 741–762.
23
Frisardi, V & Imbimbo, BP (2012) Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk. J Alzheimers Dis
30, Suppl. 2, S1–S4.
24
Craft, S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol
66, 300–305.
25
Merlo, S, Spampinato, S, Canonico, PL, et al. (2010) Alzheimer's disease: brain expression of a metabolic disorder?
Trends Endocrinol Metab
21, 537–544.
26
Luchsinger, JA (2012) Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis
30, Suppl. 2, S185–S198.
27
Moreira, PI (2012) Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis
30, Suppl. 2, S199–S215.
28
Kim, JK, Fillmore, JJ, Chen, Y, et al. (2001) Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A
98, 7522–7527.
29
Shulman, GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest
106, 171–176.
30
Yu, C, Chen, Y, Cline, GW, et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem
277, 50230–50236.
31
Borst, SE (2004) The role of TNF-alpha in insulin resistance. Endocrine
23, 177–182.
32
Ruan, H & Lodish, HF (2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev
14, 447–455.
33
Arbo, I, Halle, C, Malik, D, et al. (2011) Insulin induces fatty acid desaturase expression in human monocytes. Scand J Clin Lab Invest
71, 330–339.
34
Lopez-Ramirez, MA, Wu, D, Pryce, G, et al. (2014) MicroRNA-155 negatively affects blood–brain barrier function during neuroinflammation. FASEB J
28, 2551–2565.
35
Craft, S (2005) Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging
26, Suppl. 1, 65–69.
36
Chiu, SL, Chen, CM & Cline, HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo
. Neuron
58, 708–719.
37
Shoelson, SE, Lee, J & Goldfine, AB (2006) Inflammation and insulin resistance. J Clin Invest
116, 1793–1801.
38
Chavez, JA & Summers, SA (2012) A ceramide-centric view of insulin resistance. Cell Metab
15, 585–594.
39
Summers, SA (2006) Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res
45, 42–72.
40
van Asselt, DZ, de Groot, LC, van Staveren, WA, et al. (1998) Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr
68, 328–334.
41
Krasinski, SD, Russell, RM, Samloff, IM, et al. (1986) Fundic atrophic gastritis in an elderly population. Effect on hemoglobin and several serum nutritional indicators. J Am Geriatr Soc
34, 800–806.
42
Obeid, R & Herrmann, W (2006) Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett
580, 2994–3005.
43
Tucker, KL, Qiao, N, Scott, T, et al. (2005) High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr
82, 627–635.
44
Cropper, SS, Smith, JL & Groff, JL (2005) Advanced Nutrition and Human Metabolism, 4th ed.
Belmont, CA: Thomson Wadsworth.
45
Polidori, MC, Pientka, L & Mecocci, P (2012) A review of the major vascular risk factors related to Alzheimer's disease. J Alzheimers Dis
32, 521–530.
46
Patterson, C, Feightner, J, Garcia, A, et al. (2007) General risk factors for dementia: a systematic evidence review. Alzheimers Dement
3, 341–347.
47
Luchsinger, JA & Mayeux, R (2004) Dietary factors and Alzheimer's disease. Lancet Neurol
3, 579–587.
48
Dosunmu, R, Wu, J, Basha, MR, et al. (2007) Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother
7, 887–900.
49
Schiepers, OJ, de Groot, RH, Jolles, J, et al. (2010) Fish consumption, not fatty acid status, is related to quality of life in a healthy population. Prostaglandins Leukot Essent Fatty Acids
83, 31–35.
50
Brayne, C, Gao, L, Matthews, F, et al. (2005) Challenges in the epidemiological investigation of the relationships between physical activity, obesity, diabetes, dementia and depression. Neurobiol Aging
26, Suppl. 1, 6–10.
51
Convit, A (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging
26, Suppl. 1, 31–35.
52
Greenwood, CE & Winocur, G (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging
26, Suppl. 1, 42–45.
53
Brand-Miller, J, Hayne, S, Petocz, P, et al. (2003) Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care
26, 2261–2267.
54
Brand-Miller, JC (2003) Glycemic load and chronic disease. Nutr Rev
61, S49–S55.
55
Molteni, R, Barnard, RJ, Ying, Z, et al. (2002) A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience
112, 803–814.
56
Stangl, D & Thuret, S (2009) Impact of diet on adult hippocampal neurogenesis. Genes Nutr
4, 271–282.
57
Kanoski, SE & Davidson, TL (2011) Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol Behav
103, 59–68.
58
Poo, MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci
2, 24–32.
59
Castren, E, Berninger, B, Leingartner, A, et al. (1998) Regulation of brain-derived neurotrophic factor mRNA levels in hippocampus by neuronal activity. Prog Brain Res
117, 57–64.
60
Scarmeas, N, Stern, Y, Tang, MX, et al. (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol
59, 912–921.
61
Gu, Y, Nieves, JW, Stern, Y, et al. (2010) Food combination and Alzheimer disease risk: a protective diet. Arch Neurol
67, 699–706.
62
Solfrizzi, V, Panza, F & Capurso, A (2003) The role of diet in cognitive decline. J Neural Transm
110, 95–110.
63
Morris, MC, Evans, DA, Bienias, JL, et al. (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA
287, 3230–3237.
64
Son, TG, Camandola, S & Mattson, MP (2008) Hormetic dietary phytochemicals. Neuromolecular Med
10, 236–246.
65
Gomez-Pinilla, F (2008) Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci
9, 568–578.
66
Gomez-Pinilla, F (2008) The influences of diet and exercise on mental health through hormesis. Ageing Res Rev
7, 49–62.
67
Mattson, MP (2008) Hormesis and disease resistance: activation of cellular stress response pathways. Hum Exp Toxicol
27, 155–162.
68
Mattson, MP (2008) Dietary factors, hormesis and health. Ageing Res Rev
7, 43–48.
69
Sofi, F, Cesari, F, Abbate, R, et al. (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ
337, a1344.
70
Panagiotakos, DB, Dimakopoulou, K, Katsouyanni, K, et al. (2009) Mediterranean diet and inflammatory response in myocardial infarction survivors. Int J Epidemiol
38, 856–866.
71
Dietschy, JM (1998) Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr
128, Suppl. 2, 444S–448S.
72
Woollett, LA, Spady, DK & Dietschy, JM (1992) Regulatory effects of the saturated fatty acids 6:0 through 18:0 on hepatic low density lipoprotein receptor activity in the hamster. J Clin Invest
89, 1133–1141.
73
Woollett, LA, Spady, DK & Dietschy, JM (1992) Saturated and unsaturated fatty acids independently regulate low density lipoprotein receptor activity and production rate. J Lipid Res
33, 77–88.
74
Caggiula, AW & Mustad, VA (1997) Effects of dietary fat and fatty acids on coronary artery disease risk and total and lipoprotein cholesterol concentrations: epidemiologic studies. Am J Clin Nutr
65, Suppl. 5, 1597S–1610S.
75
Kris-Etherton, PM & Yu, S (1997) Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr
65, Suppl. 5, 1628S–1644S.
76
Kris-Etherton, PM, Yu, S, Etherton, TD, et al. (1997) Fatty acids and progression of coronary artery disease. Am J Clin Nutr
65, 1088–1090.
77
Gill, JM & Sattar, N (2009) Ceramides: a new player in the inflammation-insulin resistance paradigm?
Diabetologia
52, 2475–2477.
78
Han, X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res
2, 65–77.
79
Han, X, Holtzman, DM, McKeel, DW Jr, et al. (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem
82, 809–818.
80
Matsuzaki, K (2010) Ganglioside cluster-mediated aggregation and cytotoxicity of amyloid beta-peptide: molecular mechanism and inhibition. Yakugaku Zasshi
130, 511–515
.
81
He, X, Huang, Y, Li, B, et al. (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging
31, 398–408.
82
Grimm, MO, Haupenthal, VJ, Rothhaar, TL, et al. (2013) Effect of different phospholipids on alpha-secretase activity in the non-amyloidogenic pathway of Alzheimer's disease. Int J Mol Sci
14, 5879–5898.
83
Ascherio, A, Katan, MB, Zock, PL, et al. (1999)
Trans fatty acids and coronary heart disease. N Engl J Med
340, 1994–1998.
84
Morris, MC, Evans, DA, Bienias, JL, et al. (2003) Dietary fats and the risk of incident Alzheimer disease. Arch Neurol
60, 194–200.
85
Bowman, GL, Silbert, LC, Howieson, D, et al. (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology
78, 241–249.
86
Khan, SA & Vanden Heuvel, JP (2003) Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J Nutr Biochem
14, 554–567.
87
Vanden Heuvel, JP (2009) Cardiovascular disease-related genes and regulation by diet. Curr Atheroscler Rep
11, 448–455.
88
Vanden Heuvel, JP (2004) Diet, fatty acids, and regulation of genes important for heart disease. Curr Atheroscler Rep
6, 432–440.
89
Horrocks, LA & Farooqui, AA (2004) Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids
70, 361–372.
90
Sastry, PS (1985) Lipids of nervous tissue: composition and metabolism. Prog Lipid Res
24, 69–176.
91
Bordoni, A, Hrelia, S, Lorenzini, A, et al. (1998) Dual influence of aging and vitamin B6 deficiency on delta-6-desaturation of essential fatty acids in rat liver microsomes. Prostaglandins Leukot Essent Fatty Acids
58, 417–420.
92
Das, UN (2010) A defect in Δ6 and Δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians. Lipids Health Dis
9, 130.
93
Horrobin, DF (1981) Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses
7, 1211–1220.
94
Montuschi, P, Barnes, P & Roberts, LJ 2nd (2007) Insights into oxidative stress: the isoprostanes. Curr Med Chem
14, 703–717.
95
Oster, T & Pillot, T (2010) Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochim Biophys Acta
1801, 791–798.
96
Simopoulos, AP (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med
233, 674–688.
97
Lord, RS & Bralley, JA (2008) Laboratory Evaluations for Integrative and Functional Medicine, 2nd ed.
Georgia: Metametrix Institute.
98
Infante, JP & Huszagh, VA (1997) On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders. Mol Cell Biochem
168, 101–115.
99
Astarita, G, Jung, KM, Berchtold, NC, et al. (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One
5, e12538.
100
Kou, J, Kovacs, GG, Hoftberger, R, et al. (2011) Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol
122, 271–283.
101
Cunnane, SC (1988) Evidence that adverse effects of zinc deficiency on essential fatty acid composition in rats are independent of food intake. Br J Nutr
59, 273–278.
102
Cunnane, SC (1988) Role of zinc in lipid and fatty acid metabolism and in membranes. Prog Food Nutr Sci
12, 151–188.
103
Davidson, MH (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol
98, 27i–33i.
104
Barclay, AW, Brand-Miller, JC & Mitchell, P (2003) Glycemic index, glycemic load and diabetes in a sample of older Australians. Asia Pac J Clin Nutr
Suppl. 12, S11.
105
Havel, PJ (2005) Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev
63, 133–157.
106
Basciano, H, Federico, L & Adeli, K (2005) Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab
2, 5.
107
Kok, N, Roberfroid, M & Delzenne, N (1996) Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism
45, 1547–1550.
108
van der Borght, K, Kohnke, R, Goransson, N, et al. (2011) Reduced neurogenesis in the rat hippocampus following high fructose consumption. Regul Pept
167, 26–30.
109
Banks, WA (2008) The blood–brain barrier as a cause of obesity. Curr Pharm Des
14, 1606–1614.
110
Kokoeva, MV, Yin, H & Flier, JS (2005) Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science
310, 679–683.
111
McNay, DE, Briancon, N, Kokoeva, MV, et al. (2012) Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice. J Clin Invest
122, 142–152.
112
Migaud, M, Batailler, M, Segura, S, et al. (2010) Emerging new sites for adult neurogenesis in the mammalian brain: a comparative study between the hypothalamus and the classical neurogenic zones. Eur J Neurosci
32, 2042–2052.
113
Pierce, AA & Xu, AW (2010)
De novo neurogenesis in adult hypothalamus as a compensatory mechanism to regulate energy balance. J Neurosci
30, 723–730.
114
Funari, VA, Crandall, JE & Tolan, DR (2007) Fructose metabolism in the cerebellum. Cerebellum
6, 130–140.
115
Dauncey, MJ (2009) New insights into nutrition and cognitive neuroscience. Proc Nutr Soc
68, 408–415.
116
Kamphuis, PJ & Scheltens, P (2010) Can nutrients prevent or delay onset of Alzheimer's disease?
J Alzheimers Dis
20, 765–775.
117
Liu, J & Ames, BN (2005) Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci
8, 67–89.
118
Pieczenik, SR & Neustadt, J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol
83, 84–92.
119
Conquer, JA, Tierney, MC, Zecevic, J, et al. (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids
35, 1305–1312.
120
Rinaldi, P, Polidori, MC, Metastasio, A, et al. (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging
24, 915–919.
121
Quadri, P, Fragiacomo, C, Pezzati, R, et al. (2004) Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr
80, 114–122.
122
Baldeiras, I, Santana, I, Proenca, MT, et al. (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis
15, 117–128.
123
Dysken, MW, Sano, M, Asthana, S, et al. (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA
311, 33–44.
124
Littlejohns, TJ, Henley, WE, Lang, IA, et al. (2014) Vitamin D and the risk of dementia and Alzheimer disease. Neurology
83, 920–928.
125
Douaud, G, Refsum, H, de Jager, CA, et al. (2013) Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A
110, 9523–9528.
126
Balk, E, Chung, M, Raman, G, et al. (2006) B vitamins and berries and age-related neurodegenerative disorders. Evid Rep Technol Assess
1–161.
127
Aisen, PS, Schneider, LS, Sano, M, et al. (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA
300, 1774–1783.
128
Morris, MC, Evans, DA, Schneider, JA, et al. (2006) Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J Alzheimer's Dis
9, 435–443.
129
Smith, C, Marks, AD & Lieberman, M (2005) Protein digestion and amino acid absorption. In Marks' Basic Medical Biochemistry: A Clinical Approach, p. 695 [Smith, C, Marks, AD and Lieberman, M, editors]. Philadelphia: Lippincott Williams & Wilkins.
130
Sawada, M, Hirata, Y, Arai, H, et al. (1987) Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. J Neurochem
48, 760–764.
131
Vrecko, K, Birkmayer, JG & Krainz, J (1993) Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH). J Neural Transm Park Dis Dement Sect
5, 147–156.
132
O'Keeffe, ST (2000) Thiamine deficiency in elderly people. Age Ageing
29, 99–101.
133
Gibson, GE & Blass, JP (2007) Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid Redox Signal
9, 1605–1619.
134
Gibson, GE, Sheu, KF, Blass, JP, et al. (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol
45, 836–840.
135
Wyatt, DT, Nelson, D & Hillman, RE (1991) Age-dependent changes in thiamin concentrations in whole blood and cerebrospinal fluid in infants and children. Am J Clin Nutr
53, 530–536.
136
Singleton, CK & Martin, PR (2001) Molecular mechanisms of thiamine utilization. Curr Mol Med
1, 197–207.
137
Langlais, PJ & Zhang, SX (1993) Extracellular glutamate is increased in thalamus during thiamine deficiency-induced lesions and is blocked by MK-801. J Neurochem
61, 2175–2182.
138
Heroux, M, Raghavendra Rao, VL, Lavoie, J, et al. (1996) Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Metab Brain Dis
11, 81–88.
139
Mastrogiacoma, F, Bettendorff, L, Grisar, T, et al. (1996) Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann Neurol
39, 585–591.
140
Mastrogiacoma, F, Lindsay, JG, Bettendorff, L, et al. (1996) Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. Ann Neurol
39, 592–598.
141
Matsushita, S, Miyakawa, T, Maesato, H, et al. (2008) Elevated cerebrospinal fluid tau protein levels in Wernicke's encephalopathy. Alcohol Clin Exp Res
32, 1091–1095.
142
Zhang, Q, Yang, G, Li, W, et al. (2011) Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides. Neurobiol Aging
32, 42–53.
143
Karuppagounder, SS, Xu, H, Shi, Q, et al. (2009) Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging
30, 1587–1600.
144
Markesbery, WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med
23, 134–147.
145
Perry, G, Cash, AD & Smith, MA (2002) Alzheimer disease and oxidative stress. J Biomed Biotechnol
2, 120–123.
147
Seshadri, S, Beiser, A, Selhub, J, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med
346, 476–483.
148
Joseph, JA, Denisova, N, Fisher, D, et al. (1998) Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Ann N Y Acad Sci
854, 268–276.
149
Ames, BN, Cathcart, R, Schwiers, E, et al. (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A
78, 6858–6862.
150
Hageman, GJ & Stierum, RH (2001) Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res
475, 45–56.
151
Nakashima, Y & Suzue, R (1984) Influence of nicotinic acid on cerebroside synthesis in the brain of developing rats. J Nutr Sci Vitaminol
30, 525–534.
152
Melo, SS, Meirelles, MS, Jordao Junior, AA, et al. (2000) Lipid peroxidation in nicotinamide-deficient and nicotinamide-supplemented rats. Int J Vitam Nutr Res
70, 321–323.
153
Morris, MC, Evans, DA, Bienias, JL, et al. (2004) Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry
75, 1093–1099.
154
Battaglia, A, Bruni, G, Ardia, A, et al. (1989) Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. J Am Geriatr Soc
37, 295–302.
155
Malouf, R & Grimley Evans, J (2003) The effect of vitamin B6 on cognition. The Cochrane Database of Systematic Reviews 2003, issue 4
, CD004393.
156
Wakimoto, P & Block, G (2001) Dietary intake, dietary patterns, and changes with age: an epidemiological perspective. J Gerontol A Biol Sci Med Sci
56, 65–80.
157
Coker, M, de Klerk, JB, Poll-The, BT, et al. (1996) Plasma total odd-chain fatty acids in the monitoring of disorders of propionate, methylmalonate and biotin metabolism. J Inherit Metab Dis
19, 743–751.
158
Umhau, JC, Dauphinais, KM, Patel, SH, et al. (2006) The relationship between folate and docosahexaenoic acid in men. Eur J Clin Nutr
60, 352–357.
159
Pita, ML & Delgado, MJ (2000) Folate administration increases n-3 polyunsaturated fatty acids in rat plasma and tissue lipids. Thromb Haemost
84, 420–423.
160
Hirono, H & Wada, Y (1978) Effects of dietary folate deficiency on developmental increase of myelin lipids in rat brain. J Nutr
108, 766–772.
161
Rogaev, EI, Lukiw, WJ, Lavrushina, O, et al. (1994) The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. Genomics
22, 340–347.
162
Miller, AL (2003) The methionine–homocysteine cycle and its effects on cognitive diseases. Altern Med Rev
8, 7–19.
163
Lehmann, M, Gottfries, CG & Regland, B (1999) Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord
10, 12–20.
164
Nilsson, K, Gustafson, L & Hultberg, B (2002) Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord
14, 7–12.
165
Nilsson, K, Gustafson, L & Hultberg, B (2001) Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry
16, 609–614.
166
Snowdon, DA, Tully, CL, Smith, CD, et al. (2000) Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr
71, 993–998.
167
Kwok, T, Tang, C, Woo, J, et al. (1998) Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry
13, 611–616.
168
Evers, S, Koch, HG, Grotemeyer, KH, et al. (1997) Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol
54, 1276–1282.
169
Chambers, JC, Ueland, PM, Obeid, OA, et al. (2000) Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation
102, 2479–2483.
170
Christen, Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr
71, 621S–629S.
171
Ho, PI, Ortiz, D, Rogers, E, et al. (2002) Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res
70, 694–702.
172
White, AR, Huang, X, Jobling, MF, et al. (2001) Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem
76, 1509–1520.
173
Ho, PI, Collins, SC, Dhitavat, S, et al. (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem
78, 249–253.
174
Kruman, II, Culmsee, C, Chan, SL, et al. (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci
20, 6920–6926.
175
Olney, JW, Price, MT, Salles, KS, et al. (1987)
l-Homocysteic acid: an endogenous excitotoxic ligand of the NMDA receptor. Brain Res Bull
19, 597–602.
176
James, SJ, Melnyk, S, Pogribna, M, et al. (2002) Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr
132, Suppl. 8, 2361S–2366S.
177
West, RL, Lee, JM & Maroun, LE (1995) Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci
6, 141–146.
178
Selley, ML (2007) A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging
28, 1834–1839.
179
Werstuck, GH, Lentz, SR, Dayal, S, et al. (2001) Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest
107, 1263–1273.
180
Walker, AK, Jacobs, RL, Watts, JL, et al. (2011) A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell
147, 840–852.
181
Vance, DE, Walkey, CJ & Cui, Z (1997) Phosphatidylethanolamine N-methyltransferase from liver. Biochim Biophys Acta
1348, 142–150.
182
Resseguie, M, Song, J, Niculescu, MD, et al. (2007) Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes. FASEB J
21, 2622–2632.
183
Michel, V, Yuan, Z, Ramsubir, S, et al. (2006) Choline transport for phospholipid synthesis. Exp Biol Med
231, 490–504.
184
Wecker, L (1990) Dietary choline: a limiting factor for the synthesis of acetylcholine by the brain. Adv Neurol
51, 139–145.
185
Slotkin, TA, Nemeroff, CB, Bissette, G, et al. (1994) Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. J Clin Invest
94, 696–702.
186
Miller, BL, Jenden, DJ, Cummings, JL, et al. (1986) Abnormal erythrocyte choline and influx in Alzheimer's disease. Life Sci
38, 485–490.
187
Balmer, JE & Blomhoff, R (2002) Gene expression regulation by retinoic acid. J Lipid Res
43, 1773–1808.
188
Khanna, A & Reddy, TS (1983) Effect of undernutrition and vitamin A deficiency on the phospholipid composition of rat tissues at 21 days of age. I. Liver, spleen and kidney. Int J Vitam Nutr Res
53, 3–8.
189
Oliveros, LB, Domeniconi, MA, Vega, VA, et al. (2007) Vitamin A deficiency modifies lipid metabolism in rat liver. Br J Nutr
97, 263–272.
190
Koryakina, A, Aeberhard, J, Kiefer, S, et al. (2009) Regulation of secretases by all-trans-retinoic acid. FEBS J
276, 2645–2655.
191
Goodman, AB & Pardee, AB (2003) Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A
100, 2901–2905.
192
Shudo, K, Fukasawa, H, Nakagomi, M, et al. (2009) Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res
6, 302–311.
193
Tippmann, F, Hundt, J, Schneider, A, et al. (2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J
23, 1643–1654.
194
Corcoran, JP, So, PL & Maden, M (2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci
20, 896–902.
195
Husson, M, Enderlin, V, Delacourte, A, et al. (2006) Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol Dis
23, 1–10.
196
Acin-Perez, R, Hoyos, B, Zhao, F, et al. (2010) Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J
24, 627–636.
197
Leung, WC, Hessel, S, Meplan, C, et al. (2009) Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15′-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J
23, 1041–1053.
198
Buell, JS & Dawson-Hughes, B (2008) Vitamin D and neurocognitive dysfunction: preventing “D”ecline?
Mol Aspects Med
29, 415–422.
199
Sato, Y, Asoh, T & Oizumi, K (1998) High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone
23, 555–557.
200
Scott, TM, Peter, I, Tucker, KL, et al. (2006) The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry
21, 519–528.
201
Ogihara, T, Miya, K & Morimoto, S (1990) Possible participation of calcium-regulating factors in senile dementia in elderly female subjects. Gerontology
36, Suppl. 1, 25–30.
202
Luckhaus, C, Mahabadi, B, Grass-Kapanke, B, et al. (2009) Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease. J Neural Transm
116, 905–911.
203
Tysiewicz-Dudek, M, Pietraszkiewicz, F & Drozdzowska, B (2008) Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other?
Ortop Traumatol Rehabil
10, 315–323.
204
Sutherland, MK, Somerville, MJ, Yoong, LK, et al. (1992) Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res
13, 239–250.
205
Gezen-Ak, D, Dursun, E, Ertan, T, et al. (2007) Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med
212, 275–282.
206
Baas, D, Prufer, K, Ittel, ME, et al. (2000) Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). Glia
31, 59–68.
207
Alvarez, JA & Ashraf, A (2010) Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol
2010, 351–385.
208
Wehr, E, Pilz, S, Boehm, BO, et al. (2010) Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf)
73, 243–248.
209
Chu, LW, Tam, S, Lee, PW, et al. (2008) Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf)
68, 589–598.
210
Hogervorst, E, Bandelow, S, Combrinck, M, et al. (2004) Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol
39, 1633–1639.
211
Kinuta, K, Tanaka, H, Moriwake, T, et al. (2000) Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology
141, 1317–1324.
212
Jimenez-Jimenez, FJ, de Bustos, F, Molina, JA, et al. (1997) Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm
104, 703–710.
213
Perkins, AJ, Hendrie, HC, Callahan, CM, et al. (1999) Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol
150, 37–44.
214
Vuletic, S, Peskind, ER, Marcovina, SM, et al. (2005) Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro
. J Neurosci Res
80, 406–413.
215
Desrumaux, C, Risold, PY, Schroeder, H, et al. (2005) Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB J
19, 296–297.
216
Yatin, SM, Varadarajan, S & Butterfield, DA (2000) Vitamin E prevents Alzheimer's amyloid beta-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis
2, 123–131.
217
Butterfield, DA, Koppal, T, Subramaniam, R, et al. (1999) Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev Neurosci
10, 141–149.
218
Rota, C, Rimbach, G, Minihane, AM, et al. (2005) Dietary vitamin E modulates differential gene expression in the rat hippocampus: potential implications for its neuroprotective properties. Nutr Neurosci
8, 21–29.
219
Cutler, RG, Kelly, J, Storie, K, et al. (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A
101, 2070–2075.
220
Briefel, RR, Bialostosky, K, Kennedy-Stephenson, J, et al. (2000) Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988–1994. J Nutr
130, Suppl. 5S, 1367S–1373S.
221
Tully, CL, Snowdon, DA & Markesbery, WR (1995) Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun Study. Neuroreport
6, 2105–2108.
222
Cuajungco, MP & Faget, KY (2003) Zinc takes the center stage: its paradoxical role in Alzheimer's disease. Brain Res Brain Res Rev
41, 44–56.
223
Loef, M, von Stillfried, N & Walach, H (2012) Zinc diet and Alzheimer's disease: a systematic review. Nutr Neurosci
15, 2–12.
224
Stoltenberg, M, Bush, AI, Bach, G, et al. (2007) Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience
150, 357–369.
225
Black, MM (2003) Micronutrient deficiencies and cognitive functioning. J Nutr
133, Suppl. 2, 3927S–3931S.
226
Bhatnagar, S & Taneja, S (2001) Zinc and cognitive development. Br J Nutr
85, Suppl. 2, S139–S145.
227
Huang, X, Atwood, CS, Hartshorn, MA, et al. (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry
38, 7609–7616.
228
Huang, X, Cuajungco, MP, Atwood, CS, et al. (2000) Alzheimer's disease, beta-amyloid protein and zinc. J Nutr
130, Suppl. 5S, 1488S–1492S.
229
Atamna, H (2006) Heme binding to amyloid-beta peptide: mechanistic role in Alzheimer's disease. J Alzheimers Dis
10, 255–266.
230
Atamna, H & Boyle, K (2006) Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc Natl Acad Sci U S A
103, 3381–3386.
231
Sensi, SL & Jeng, JM (2004) Rethinking the excitotoxic ionic milieu: the emerging role of Zn(2+) in ischemic neuronal injury. Curr Mol Med
4, 87–111.
232
Furuta, A, Price, DL, Pardo, CA, et al. (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol
146, 357–367.
233
Leissring, MA, Farris, W, Wu, X, et al. (2004) Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J
383, 439–446.
234
Jayasooriya, AP, Ackland, ML, Mathai, ML, et al. (2005) Perinatal omega-3 polyunsaturated fatty acid supply modifies brain zinc homeostasis during adulthood. Proc Natl Acad Sci U S A
102, 7133–7138.
235
Suphioglu, C, De Mel, D, Kumar, L, et al. (2010) The omega-3 fatty acid, DHA, decreases neuronal cell death in association with altered zinc transport. FEBS Lett
584, 612–618.
236
Potocnik, FC, van Rensburg, SJ, Hon, D, et al. (2006) Oral zinc augmentation with vitamins A and D increases plasma zinc concentration: implications for burden of disease. Metab Brain Dis
21, 139–147.
237
Wang, J, Fivecoat, H, Ho, L, et al. (2010) The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochim Biophys Acta
1804, 1690–1694.
238
Donmez, G, Wang, D, Cohen, DE, et al. (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10
. Cell
142, 320–332.
239
Costa, RM, Drew, C & Silva, AJ (2005) Notch to remember. Trends Neurosci
28, 429–435.
240
Bonda, DJ, Lee, HG, Camins, A, et al. (2011) The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol
10, 275–279.
241
Civitarese, AE, Carling, S, Heilbronn, LK, et al. (2007) Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med
4, e76.
242
Xue, B, Yang, Z, Wang, X, et al. (2012) Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLOS ONE
7, e45990.
243
Wu, A, Ying, Z & Gomez-Pinilla, F (2007) Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma
24, 1587–1595.
244
Hong, YT, Veenith, T, Dewar, D, et al. (2014) Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol
71, 23–31.
245
Lye, TC & Shores, EA (2000) Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol Rev
10, 115–129.
246
Nemetz, PN, Leibson, C, Naessens, JM, et al. (1999) Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol
149, 32–40.
247
Borra, MT, Smith, BC & Denu, JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem
280, 17187–17195.
248
Allard, JS, Perez, E, Zou, S, et al. (2009) Dietary activators of Sirt1. Mol Cell Endocrinol
299, 58–63.
249
Maher, P, Akaishi, T & Abe, K (2006) Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci U S A
103, 16568–16573.
250
Ansari, MA, Abdul, HM, Joshi, G, et al. (2009) Protective effect of quercetin in primary neurons against Abeta(1–42): relevance to Alzheimer's disease. J Nutr Biochem
20, 269–275.
251
Craft, NE, Haitema, TB, Garnett, KM, et al. (2004) Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging
8, 156–162.
252
Johnson, EJ (2012) A possible role for lutein and zeaxanthin in cognitive function in the elderly. Am J Clin Nutr
96, 1161S–1165S.
253
GM, Cole, Lim, GP, Yang, F, et al. (2005) Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging
26, Suppl. 1, 133–136.
254
Venkatesan, P & Rao, MN (2000) Structure–activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J Pharm Pharmacol
52, 1123–1128.
255
Aggarwal, BB, Kumar, A & Bharti, AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res
23, 363–398.
256
Lim, GP, Chu, T, Yang, F, et al. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci
21, 8370–8377.
257
Baum, L, Lam, CW, Cheung, SK, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol
28, 110–113.
258
Ringman, JM, Frautschy, SA, Teng, E, et al. (2012) Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther
4, 43.
259
Hyung, SJ, DeToma, AS, Brender, JR, et al. (2013) Insights into antiamyloidogenic properties of the green tea extract ( − )-epigallocatechin-3-gallate toward metal-associated amyloid-beta species. Proc Natl Acad Sci U S A
110, 3743–3748.
260
Lee, MJ, Maliakal, P, Chen, L, et al. (2002) Pharmacokinetics of tea catechins after ingestion of green tea and ( − )-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev
11, 1025–1032.
261
Vepsalainen, S, Koivisto, H, Pekkarinen, E, et al. (2013) Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer's disease. J Nutr Biochem
24, 360–370.
262
Hartman, RE, Shah, A, Fagan, AM, et al. (2006) Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis
24, 506–515.
263
Ye, J, Meng, X, Yan, C, et al. (2010) Effect of purple sweet potato anthocyanins on beta-amyloid-mediated PC-12 cells death by inhibition of oxidative stress. Neurochem Res
35, 357–365.
264
Gutierres, JM, Carvalho, FB & Schetinger, MR (2014) Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer's type. Life Sci
96, 7–17.
265
Zeisel, SH & Blusztajn, JK (1994) Choline and human nutrition. Ann Rev Nutr
14, 269–296.
